Fiche société
Amgen
Traitements, essais et publications liés.
Traitements23programmes
Essais14liés
Publications16liées
SourceDBlocale
Traitements
23| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| AMG334The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments. | Migraine | Phase 4 | À vérifier | United States, Argentina, Austria, Belgium, Czechia, Finland, France, Germany, … | À vérifier |
| BlinatumomabThe goal of this clinical trial is to evaluate the efficacy and safety of Blinatumomab in the treatment of refractory myasthenia gravis, with the expectation of offering a new therapeutic option for refractory patients. The main questions it aims to answer are: * Does Blinatumomab improve patients' clinical symptoms? * Is Blinatumomab safe for the treatment of myasthenia gravis? Participants will: * Receive two cycles of intravenous Blinatumomab infusion, each lasting 5 days, with a 1-week interval between cycles. * Visit the clinic once every 4 weeks for checkups and tests. * Keep a diary of their symptoms and the types and dosages of medications. | Lupus, Myasthénie | Phase 2 | Traitement symptomatique | United States, Australia, Belgium, France, Germany, Italy, Portugal, Spain, … | À vérifier |
| ErenumabThe primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity. | Migraine | Phase 4 | Traitement symptomatique | United States, Bulgaria, Czechia, Hungary, Italy, Poland, Portugal, Romania, … | À vérifier |
| Erenumab Dose 1This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP). | Migraine | Phase 3 | À vérifier | United States, Belgium, Canada, Colombia, Finland, Germany, Hungary, Italy, … | À vérifier |
| Erenumab Dose 2This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP). | Migraine | Phase 3 | À vérifier | United States, Belgium, Canada, Colombia, Finland, Germany, Hungary, Italy, … | À vérifier |
| Erenumab Dose 3This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP). | Migraine | Phase 3 | À vérifier | United States, Belgium, Canada, Colombia, Finland, Germany, Hungary, Italy, … | À vérifier |
| InebilizumabThe main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B). | Lupus, Myasthénie | Phase 2 | À vérifier | United States, Argentina, Brazil, France, Poland, Spain | À vérifier |
| Oral ProphylacticThe purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments. | Migraine | Phase 4 | À vérifier | United States, Argentina, Austria, Belgium, Czechia, Finland, France, Germany, … | À vérifier |
| SotorasibThe primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy. | Cancer | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, … | À vérifier |
| BlinatumomabThe goal of this clinical trial is to evaluate the efficacy and safety of Blinatumomab in the treatment of refractory myasthenia gravis, with the expectation of offering a new therapeutic option for refractory patients. The main questions it aims to answer are: * Does Blinatumomab improve patients' clinical symptoms? * Is Blinatumomab safe for the treatment of myasthenia gravis? Participants will: * Receive two cycles of intravenous Blinatumomab infusion, each lasting 5 days, with a 1-week interval between cycles. * Visit the clinic once every 4 weeks for checkups and tests. * Keep a diary of their symptoms and the types and dosages of medications. | Myasthénie | Phase 2 | Traitement symptomatique | À vérifier | |
| Erenumab Dose 1This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP). | Migraine | Phase 3 | À vérifier | United States, Belgium, Canada, Colombia, Finland, Germany, Hungary, Italy, Japan, Poland, Portugal, Puerto Rico, Russia, Spain, Switzerland, United Kingdom | À vérifier |
| ErenumabThe primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity. | Migraine | Phase 4 | Traitement symptomatique | United States, Bulgaria, Czechia, Hungary, Italy, Poland, Portugal, Romania, Spain | À vérifier |
| InebilizumabThe main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B). | Lupus | Phase 2 | United States, Australia, Belgium, France, Germany, Italy, Portugal, Spain, United Arab Emirates, United Kingdom | À vérifier | |
| InebilizumabThe main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B). | Myasthénie | Phase 2 | À vérifier | United States, Argentina, Brazil, France, Poland, Spain | À vérifier |
| ErenumabThe primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity. | Migraine | À vérifier | Traitement symptomatique | Austria | À vérifier |
| ErenumabThe primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity. | Migraine | Phase 4 | Traitement symptomatique | Germany | À vérifier |
| ErenumabThe primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity. | Migraine | Phase 4 | Traitement symptomatique | United States | À vérifier |
| InebilizumabThe main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B). | Myasthénie | Phase 3 | À vérifier | United States, Argentina, Belarus, Brazil, Canada, China, Denmark, France, Germany, India, Italy, Japan, Poland, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye), Ukraine | À vérifier |
| Erenumab Dose 1This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to \<12 years) and adolescents (12 to \<18 years) with episodic migraine. The study hypothesis is that in pediatric participants with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP). | Migraine | Phase 3 | À vérifier | United States, Belgium, Canada, Colombia, Finland, Germany, Hungary, Italy, Japan, Poland, Puerto Rico, Russia, United Kingdom | À vérifier |
| ErenumabThe primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity. | Migraine | Phase 4 | Traitement symptomatique | Denmark, Iceland | À vérifier |
| AMG334The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments. | Migraine | Phase 4 | À vérifier | United States, Argentina, Austria, Belgium, Czechia, Finland, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, Poland, Portugal, Slovakia, Spain, United Kingdom | À vérifier |
| ErenumabThe primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity. | Migraine | À vérifier | Traitement symptomatique | Austria | À vérifier |
| SotorasibThe primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy. | Cancer | Phase 3 | Ralentissement de la progression | United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hong Kong, Hungary, Italy, Japan, … | À vérifier |
Essais cliniques
14| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Sotorasib | Cancer | Phase 3 | NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | RECRUITING |
| Erenumab | Migraine | À vérifier | NCT05281770 | Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study | UNKNOWN |
| AMG334 | Migraine | Phase 4 | NCT03927144 | Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients | COMPLETED |
| Erenumab | Migraine | Phase 4 | NCT04265755 | INTERROGATE — Biomarker and Genetic Predictors of Erenumab Treatment Response | COMPLETED |
| Erenumab Dose 1 | Migraine | Phase 3 | NCT03832998 | OASIS(CM) — Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine | COMPLETED |
| Inebilizumab | Myasthénie | Phase 3 | NCT04524273 | MINT — Myasthenia Gravis Inebilizumab Trial | ACTIVE_NOT_RECRUITING |
| Erenumab | Migraine | Phase 4 | NCT04825678 | A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine | COMPLETED |
| Erenumab | Migraine | Phase 4 | NCT04084314 | APOLLON — Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study | COMPLETED |
| Erenumab | Migraine | À vérifier | NCT04628429 | CGRP-1 — CGRP Inhibition, Autonomic Function, and Migraine | RECRUITING |
| Inebilizumab | Myasthénie | Phase 2 | NCT06987539 | THYME — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG) | RECRUITING |
| Inebilizumab | Lupus | Phase 2 | NCT06570798 | A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | RECRUITING |
| Erenumab | Migraine | Phase 4 | NCT04252742 | EMBRACE — Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine | COMPLETED |
| Erenumab Dose 1 | Migraine | Phase 3 | NCT03836040 | OASIS(EM) — Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine | ACTIVE_NOT_RECRUITING |
| Blinatumomab | Myasthénie | Phase 2 | NCT06836973 | Blinatumomab for Treatment of Refractory Myasthenia Gravis | NOT_YET_RECRUITING |
Publications
16| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Erenumab | Advice to Health Care Providers: Achieving Successful Organ Donation. | The American journal of medicine | ||
| Erenumab | Consumption of Ultra-Processed Foods and Increased Risks of Prostate Cancer in a Random Sample of United States Adults. | The American journal of medicine | ||
| Erenumab Dose 2 | Neuro-Immune Axis in Trauma-Induced Heterotopic Ossification: Mechanisms and Therapeutic Implications. | Cells | ||
| Erenumab Dose 1 | Erenumab for Chronic Cluster Headache: A Randomized Clinical Trial. | JAMA network open | ||
| Erenumab Dose 1 | Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo-Controlled Study. | European journal of neurology | ||
| Erenumab Dose 1 | Effects of erenumab on migraine aura frequency: a REFORM study. | The journal of headache and pain | ||
| Inebilizumab | Psychiatric comorbidities cluster early after onset in MOGAD: a cross-sectional comparative study with MS and NMOSD. | Journal of neurology, neurosurgery, and psychiatry | ||
| Blinatumomab | Optimizing safety and efficacy of asparaginase and blinatumomab therapy in frontline acute lymphoblastic leukemia regimens in diverse health care settings-international expert consensus. | Cancer | ||
| Blinatumomab | Derivation of an occupational exposure limit (OEL) for a potent bispecific protein-Blinatumomab (BLINCYTO®). | Regulatory toxicology and pharmacology : RTP | ||
| Blinatumomab | Cytokine release syndrome mimicking drug reaction with eosinophilia and systemic syndrome (DRESS) in a patient on blinatumomab therapy. | JAAD case reports | ||
| Inebilizumab | Neuroimmunological overlap syndromes in optic neuritis, myelitis, and connective tissue diseases. | Frontiers in neurology | ||
| Inebilizumab | Management of Exacerbations and Rescue Therapy: A Prespecified Analysis of the Phase 3 Myasthenia Gravis Inebilizumab Randomized Clinical Trial. | JAMA neurology | ||
| Blinatumomab | Dynamics of in vivo immune remodeling in Ph all patients receiving frontline ponatinib and blinatumomab therapy. | Blood cancer journal | ||
| Blinatumomab | Fatal Neuroinvasive Astrovirus VA1 Encephalitis in a Child With High-Risk B-ALL Receiving Blinatumomab. | Pediatric blood & cancer | ||
| Blinatumomab | Efficacy of blinatumomab for dermatomyositis/SLE overlap syndrome occurring after allogeneic hematopoietic stem cell transplant performed for acute lymphoblastic leukemia. | Bone marrow transplantation | ||
| Blinatumomab | Results of second-line therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. | Cancer |